Godet G, Bertrand M, Van de Steen E, Boccara G, Koskas F
Département d'anesthésie-réanimation, hôpital Pitié-Salpêtrière, 75013 Paris, France.
Ann Fr Anesth Reanim. 2001 Jan;20(1):50-3. doi: 10.1016/s0750-7658(00)00333-6.
Pathogenesis, frequency, and management of heparin-induced thrombocytopaenia are well-known. They may be related with both unfractioned heparin and low-molecular weight heparin. Suspected heparin must be discontinued as soon as the diagnosis is established. Orgaran (danaparoid sodium) may be used for management of patients with heparin-associated thrombocytopaenia but can itself be associated with a thrombocytopaenia. Our case report allows us to catch in mind such a crossed complication.
肝素诱导的血小板减少症的发病机制、发生率及处理方法已为人熟知。它与普通肝素和低分子肝素均有关。一旦确诊，必须立即停用可疑的肝素。奥加诺（达那肝素钠）可用于治疗肝素相关性血小板减少症患者，但它本身也可能与血小板减少症有关。我们的病例报告让我们记住了这样一种交叉并发症。
